Evidence map›Paper›PMID 40910201›Full record

ReviewCurrent pharmaceutical design2026

Recent Advances in Possible Treatment Options Including Herbal Remedies for the Management of Cholelithiasis.

Afridi Shafik Chabru, Ankita Das, Amoolya Sree, Payel Chakraborty, Surjeet Dhiman, Rimpa Karmakar, Abhinab Goswami, Tamilvanan Shunmugaperumal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Afridi Shafik ChabruDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Guwahati, Sila Katamur (Halugurisuk), Changsari, Kamrup, Assam, 781101, India.
Ankita DasDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Guwahati, Sila Katamur (Halugurisuk), Changsari, Kamrup, Assam, 781101, India.
Amoolya SreeDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Guwahati, Sila Katamur (Halugurisuk), Changsari, Kamrup, Assam, 781101, India.
Payel ChakrabortyDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Guwahati, Sila Katamur (Halugurisuk), Changsari, Kamrup, Assam, 781101, India.
Surjeet DhimanDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Guwahati, Sila Katamur (Halugurisuk), Changsari, Kamrup, Assam, 781101, India.
Rimpa KarmakarDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Guwahati, Sila Katamur (Halugurisuk), Changsari, Kamrup, Assam, 781101, India.
Abhinab GoswamiDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Guwahati, Sila Katamur (Halugurisuk), Changsari, Kamrup, Assam, 781101, India.
Tamilvanan ShunmugaperumalDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Guwahati, Sila Katamur (Halugurisuk), Changsari, Kamrup, Assam, 781101, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholelithiasis, particularly cholesterol-bearing-stones, is one of the gastrointestinal diseases representing a substantial global health burden. The five key primary factors inducing cholesterol-bearing-stones include genetics, hepatic cholesterol hypersecretion, rapid phase transition of cholesterol, gallbladder hypomotility, and specific intestinal factors. To date, laparoscopic cholecystectomy remains the primary treatment approach for cholelithiasis patients. The various non-surgical methods, such as bile acid therapy, novel drug candidates, and herbal remedies, are detailed. Special attention is paid to the development of ursodeoxycholic acid (UDCA)-embedded formulations. Because the UDCA is a biopharmaceutical classification system class II drug, it poses the challenge of low aqueous solubility and thus, limited oral bioavailability. Additionally, promising developments in novel drug candidates (e.g., alirocumab), probiotics, stents, and herbal treatments with purported gallstone-dissolving properties are highlighted. The development of effective non-surgical treatments like various UDCA formulations and novel drug candidates is crucial. Additionally, the integration of herbal remedies into mainstream treatment protocols could offer significant benefits. Future research should focus on optimizing these therapies and exploring personalized treatment. Furthermore, emerging curative approaches such as gene-tailored therapy hold a future direction with a concrete perspective.

Indexed as

CholelithiasisPhytotherapyPlant PreparationsAnimalsHumansUrsodeoxycholic AcidPlant PreparationsUrsodeoxycholic AcidCholelithiasischolesterolgallstonesherbal medicinesoctreotideursodeoxycholic acid

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.